Moreover, in a depression mice model glycyrrhizic acid prevented the activated enzymes in KP and the development of depressive-like behaviors [251] Therefore, it was suggested that these KP inhibitors could represent a viable therapeutic target in treating schizophrenia and other diseases associated with neuroinflammation and oxidative stress. This evidence concerns the gene NPPA and schizophrenia.